Multicenter comparison of the contraceptive ring and patch - A randomized controlled trial

被引:62
作者
Creinin, Mitchell D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Meyn, Leslie A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Borgatta, Lynn [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Barnhart, Kurt [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Jensen, Jeff [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Burke, Anne E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Westhoff, Carolyn [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Gilliam, Melissa [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Dutton, Caryn [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Ballagh, Susan A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
机构
[1] Univ Pittsburgh, Sch Med, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Pittsburgh, PA 15213 USA
[3] Boston Univ, Dept Obstet, Boston, MA USA
[4] Boston Univ, Dept Gynecol, Boston, MA USA
[5] Univ Penn, Med Ctr, Dept Epidemiol, Philadelphia, PA 19104 USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Univ Wisconsin, Madison, WI USA
[10] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
关键词
D O I
10.1097/01.AOG.0000298338.58511.d1
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To understand if the contraceptive ring or patch was more acceptable, as measured primarily by continuation, to women using an oral contraceptive and interested in a nondaily, combined hormonal contraceptive. METHODS: Five hundred women were randomly assigned to use the contraceptive ring (n=249) or contraceptive patch (n=251) for four consecutive menstrual cycles, starting with their next menses. Participants returned for a single follow-up visit during the fourth cycle for an evaluation, which included a questionnaire to assess acceptability and adverse effects. RESULTS: Rates of completion of three cycles were 94.6% (95% confidence interval [CI] 91.0-97.1%) and 88.2% (95% CI 83.4-92.0%) for ring and patch users, respectively (P=.03). Of these women, 71.0% (95% CI 64.8-76.6%) and 26.5% (95% CI 21.0-32.6%), respectively, planned to continue their method after the study (P<.001). Women switching to the patch were significantly more likely than women switching to the ring to experience longer periods (38% compared with 9%), increased dysmenorrhea (29% compared with 16%), frequent nausea (8% compared with 1%), frequent mood swings (14% compared with 8%), and frequent skin rash (12% compared with 2%) and were less likely to experience frequent vaginal discharge (8% compared with 17%). Ring users preferred the ring to the oral contraceptive (P<.001), and patch users preferred the oral contraceptive to the patch (P<.001). Nugent scores increased only in patch users (P=.01), although most of these women were asymptomatic.
引用
收藏
页码:267 / 277
页数:11
相关论文
共 19 条
[1]   Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone [J].
Ahrendt, Hans-Joachim ;
Nisand, Israel ;
Bastianelli, Carlo ;
Gomez, Maria Angeles ;
Gemzell-Danielsson, Kristina ;
Urdl, Wolfgang ;
Karskov, Birgit ;
Oeyen, Luc ;
Bitzer, Johannes ;
Page, Geert ;
Milsom, Ian .
CONTRACEPTION, 2006, 74 (06) :451-457
[2]   Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial [J].
Audet, MC ;
Moreau, M ;
Koltun, WD ;
Waldbaum, AS ;
Shangold, G ;
Fisher, AC ;
Creasy, GW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2347-2354
[3]   Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol [J].
Bjarnadóttir, RI ;
Tuppurainen, M ;
Killick, SR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (03) :389-395
[4]   Transdermal hormonal contraception: benefits and risks [J].
Burkman, Ronald T. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (02) :134.e1-134.e6
[5]   Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring [J].
Dieben, TOM ;
Roumen, FJME ;
Apter, D .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :585-593
[6]  
HOLM S, 1979, SCAND J STAT, V6, P65
[7]  
Mosher William D, 2004, Adv Data, P1
[8]   Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods [J].
Murthy, AS ;
Creinin, MD ;
Harwood, B ;
Schreiber, CA .
CONTRACEPTION, 2005, 72 (05) :333-336
[9]   Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing® [J].
Novák, A ;
de la Loge, C ;
Abetz, L .
PHARMACOECONOMICS, 2004, 22 (04) :245-256
[10]   Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial [J].
Oddsson, K ;
Leifels-Fischer, B ;
de Melo, NR ;
Wiel-Masson, D ;
Benedetto, C ;
Verhoeven, CHJ ;
Dieben, TOM .
CONTRACEPTION, 2005, 71 (03) :176-182